Diabetes Care: Relationship between aminomate esterification HDL and death outcomes in people with type 2 diabetes

Amino methylation is part of the aging process and can lead to adverse changes in protein structure and function.
lipoproteins are susceptible to amino methylation.
a recent study published in Diabetes Care, an authoritative journal in the field of diabetes, researchers aimed at assessing the effectiveness of HDL in amino methylate as a prognostic indicator of survival in patients with type 2 diabetes and its relationship to outcomes of death.
researchers used ELISA to measure amino methylated HDL in the plasma of 1,517 people with type 2 diabetes.
the study's main outcome was all-cause mortality, with secondary outcomes being deaths for specific causes, including cardiovascular, kidney, infection and cancer-related deaths.
during the 14-year mid-year follow-up period, 292 patients died, with a mortality rate of 14.5 per 1,000 people per year.
high levels of plasma amino methamphetamine HDL in patients with fatal outcomes (46.1±17.8 μg/mL vs. 32.9±10.7; P.lt;0.01).
the third highest level of aminomate esterification HDL (risk ratio of 2.11; 95% CI is 1.40-3.17; P.lt;0.d) 001) and the fourth quarterile (HR is 6.55; 95% CI is 4.67-9.77; P-lt;0.001) increased the risk of death.
after adjusting for conventional risk factors, elevated HDL aminomate esterification was independently associated with total cause mortality (HR 1.39; 95% CI was 1.28-1.52; P-lt;0.001) and all specific causes of mortality.
researchers added plasma aminomate hdl levels to multivariate models to improve the effectiveness of predicting all-cause mortality, and the C index (from 0.78 to 0.80; P.lt;0.001) increased significantly, as did the net reclassification index and comprehensive discernment.
, it can be seen that HDL's aminomate esterification can lead to HDL dysfunction, and urethane HDL is independently associated with the outcome of death in people with type 2 diabetes.